熱門資訊> 正文

Reviva Pharmaceuticals GAAP每股收益为-0.25美元

2024-05-14 22:50

Reviva Pharmaceuticals press release (NASDAQ:RVPH): Q1 GAAP EPS of -$0.25.
As of March 31, 2024, the Company’s cash totaled approximately $12.0 million compared to approximately $23.4 million as of December 31, 2023.

More on Reviva Pharmaceuticals

Reviva reports FDA acceptance of 4-week RECOVER-2 study for its schizophrenia treatment
Seeking Alpha’s Quant Rating on Reviva Pharmaceuticals
Historical earnings data for Reviva Pharmaceuticals
Financial information for Reviva Pharmaceuticals

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。